A Real-World Assessment of the demographic, clinical characteristics and outcomes of a Brazilian cohort of Previously Untreated Extensive Stage-Small Cell Lung Cancer receiving Durvalumab combined with Platinum-Etoposide in (ES-SCLC) in Brazil - EDUR-BRA

Inclusion Criteria

• - Have a documented diagnosis of ES-SCLC (newly diagnosed patients, as well as limited stage relapsed patients, are eligible);
• - Have been treated with a durvalumab-based regimen for 1L ES-SCLC in the past (retrospective) OR is currently being treated with a durvalumab-based regimen for 1L ES-SCLC (prospective);
• - Male or female adult patients ≥ 18 years of age (as per local Durvalumab approved label);
• - Provision of consent in a signed informed consent form (ICF) (allowing for data to be captured from existing medical records). If the patient´s data is entirely retrospective (i.e., the patient already presented progression, death, or completed 18 months of durvalumab-based treatment), the ICF may be waived, as decided by the local ethics committee.